Premium
Secretory carcinoma of the major salivary gland: Provincial population‐based analysis of clinical behavior and outcomes
Author(s) -
Ayre Gareth,
Hyrcza Martin,
Wu Jonn,
Berthelet Eric,
Skálová Alena,
Thomson Tom
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25536
Subject(s) - acinic cell carcinoma , salivary gland , medicine , salivary gland cancer , population , cohort , lymph node , carcinoma , adenocarcinoma , disease , oncology , pathology , gastroenterology , mucoepidermoid carcinoma , cancer , environmental health
Abstract Background Our aim was to identify the number of cases of secretory carcinoma (SC) of the major salivary gland in a population‐based cohort and review its clinical behavior with long‐term follow‐up. Methods All malignant salivary gland tumors (MSGTs) diagnosed between 1980 and 2014 were assessed for histological features compatible with SC and 140 were selected for further analysis. Results Twenty two new cases of SC were identified, 19 of which were originally classified as acinic cell carcinoma, and 3 as adenocarcinoma, not otherwise specified (NOS). Lymph node involvement was less common in SC tumors (5%) than in the control group (11%). Disease recurrence was seen less frequently in SC (9%) than the control group (20%). Mean disease‐free survival was 192 months for SC compared with 162 months for controls ( P = 0.15). Conclusion The clinical course of SC is typically indolent with a low risk of relapse not significantly different from other low‐grade MSGT.